Codexis uses its CodeEvolver® protein engineering platform technology to develop an enzyme therapeutic candidate for the potential treatment of phenylketonuria (PKU) via oral administration
8 December 2014 | By Codexis
Codexis, Inc. announced that it has developed a novel enzyme therapeutic product candidate for the potential treatment of phenylketonuria (PKU) via oral administration...